Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
>8,500 samples and 100 million cells of high resolution and fully annotated spatial proteomics data available
MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Enable Medicine, a real-world data company providing AI-ready patient, cellular and molecular data, today announced a groundbreaking collaboration to deliver the largest commercially available single-cell spatial proteomics atlas to the research and clinical community.
Enable Medicine's Pan-Cancer Atlas is a unique multi-modal dataset built using Akoya's PhenoCycler®-Fusion (PCF) platform and includes the PhenoCode™ Discovery IO60 panel as its foundational data. The Enable Atlas comprises over 100 million single cells, spanning 8,500+ samples and 15+ cancer types, with rich cellular features, including up to 60 protein biomarkers, accompanying H&E images and spatial transcriptomics measurements, and comprehensive clinical metadata.
The Enable Atlas is curated, standardized, and commercially licensable. It provides immediate value to biopharma researchers and AI model developers seeking to accelerate biomarker discovery, drug development, and translational insights. It is a special mechanism for new and existing PhenoCycler-Fusion customers to further power their experiments by integrating their data with the Enable Atlas.
'The Enable Atlas is a catalytic resource for our customers,' said Niro Ramachandran, Chief Business Officer at Akoya Biosciences. 'Biopharma customers now have the potential to generate new hypotheses from existing data, increase the statistical power of their studies, and identify novel cellular phenotypes at a scale never before possible.'
Built for scale. Designed for discovery.
The Enable Atlas's spatial proteomics layer was generated using Akoya's PhenoCycler-Fusion, the industry's fastest and most scalable spatial biology platform, and included the ultrahigh-plex IO60 panel, capturing broad biological diversity across tissue types.
Enable Medicine's software platform hosts the dataset and makes it easily explorable, allowing users to filter and subset by biomarker expression, tissue type, clinical metadata, and more. These analytical and annotation capabilities make the Atlas a powerful tool for biomarker discovery, comparative analysis, and statistical validation in discovery and translational research.
'Our strategy to map disease and provide insightful biological data requires technologies that scale. PhenoCycler-Fusion and IO60 made this possible — this combination uniquely powered the generation of our large, high-resolution, and biologically rich proteomic dataset,' said Aaron Mayer, Chief Scientific Officer at Enable Medicine. 'This level of multiplexing, throughput, and consistency was essential to create a resource that's not only comprehensive but immediately impactful in therapeutic, diagnostic, and scientific research settings.'
Key features of the Enable Pan-Cancer Atlas:
Unmatched scale and depth: Over 100 million spatially profiled single cells
High-dimensional data: up to 60 protein markers with spatial context, H&E, and spatial transcriptomics data on select samples
Diverse sample coverage: 8,500+ samples across 15+ cancer indications and normal tissues
Rich metadata: Clinical context to power translational insights
Immediate usability: Licensable and structured for downstream analysis
Meet Us at AACR 2025
The Spatial Atlas will be showcased at the upcoming American Association for Cancer Research (AACR) Annual Meeting, offering attendees a first look at this new spatial proteomics resource.
Location: Akoya Booth #3045 | April 27 | 4:30–5:00 PM
A live demonstration of the Atlas will be available during the scheduled session. Members of the Akoya and Enable Medicine teams will be on-site to discuss how the dataset can be applied to translational research, biomarker discovery, and drug development programs. For more information, visit https://sb.akoyabio.com/aacr2025.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences' mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.
About Enable Medicine
Enable Medicine is a real-world data company unlocking new insights into human disease via integrated patient, cellular and molecular information. The company offers AI-ready biological data, data management tools and data analysis services to fuel the development of large multimodal foundational models, diagnostics and drug development. Enable Medicine's data solutions support science spanning the discovery of novel therapeutic targets to assist with better clinical trial design. To learn more about Enable, visit www.enablemedicine.com.
Akoya Forward-Looking Statements
This press release contains forward-looking statements that are based on Akoya management's beliefs and assumptions and on information currently available to Akoya management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements concerning the capabilities and potential of Akoya's products and services, its collaboration with Enable Medicine, its future performance and its plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents Akoya files with the Securities and Exchange Commission from time to time. The reader is cautioned that forward-looking statements are based on a combination of facts and factors currently known by Akoya and Akoya's projections of the future, about which Akoya cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Akoya's views as of the date hereof. Akoya undertakes no obligation to update any forward-looking statements for any reason, except as required by law.
Investor Contact:
Priyam Shah
investors@akoyabio.com
Media Contact:
Ritu Mihani
media@akoyabio.com
Enable Medicine Business Development Contact:
Jess Werlin
bd@enablemedicine.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Nvidia chief calls AI ‘the greatest equalizer' — but warns Europe risks falling behind
PARIS (AP) — Will artificial intelligence save humanity — or destroy it? Lift up the world's poorest — or tighten the grip of a tech elite? Jensen Huang, the global chip tycoon, offered his opinion on Wednesday: neither dystopia nor domination. AI, he said, is a tool for liberation. Wearing his signature biker jacket and mobbed by fans for selfies, the Nvidia CEO cut the figure of a tech rockstar as he took the stage at VivaTech in Paris. 'AI is the greatest equalizer of people the world has ever created,' Huang said, kicking off one of Europe's biggest technology industry fairs. But beyond the sheeny optics, Nvidia used the Paris summit to unveil a wave of infrastructure announcements across Europe, signaling a dramatic expansion of the AI chipmaker's physical and strategic footprint on the continent. In France, the company is deploying 18,000 of its new Blackwell chips with startup Mistral AI. In Germany, it's building an industrial AI cloud to support manufacturers. Similar rollouts are underway in Italy, Spain, Finland and the U.K., including a new AI lab in Britain. Other announcements include a partnership with AI startup Perplexity to bring sovereign AI models to European publishers and telecoms, a new cloud platform with Mistral AI, and work with BMW and Mercedes-Benz to train AI-powered robots for use in auto plants. The announcements reflect how central AI infrastructure has become to global strategy, and how Nvidia — the world's most valuable chipmaker — is positioning itself as the engine behind it. At the center of the debate is Huang's concept of the AI factory: not a plant that makes goods, but a vast data center that creates intelligence. These facilities train language models, simulate new drugs, detect cancer in scans, and more. Asked if such systems risk creating a 'technological priesthood' — hoarding computing power and stymying the bottom-up innovation that fueled the tech industry for the past 50 years — Huang pushed back. 'Through the velocity of our innovation, we democratize,' he told The Associated Press. 'We lower the cost of access to technology.' As Huang put it, these factories 'reason,' 'plan,' and 'spend a lot of time talking to' themselves, powering everything from ChatGPT to autonomous vehicles and diagnostics. But some critics warn that without guardrails, such all-seeing, self-reinforcing systems could go the way of Skynet in ' The Terminator ' movie — vast intelligence engines that outpace human control. 'Just as electricity powered the last industrial revolution, AI will power the next one,' he said. 'Every country now needs a national intelligence infrastructure.' He added: 'AI factories are now part of a country's infrastructure. That's why you see me running around the world talking to heads of state — they all want AI to be part of their infrastructure. They want AI to be a growth manufacturing industry for them.' Europe, long praised for its leadership on digital rights, now finds itself at a crossroads. As Brussels pushes forward with world-first AI regulations, some warn that over-caution could cost the bloc its place in the global race. With the U.S. and China surging ahead and most major AI firms based elsewhere, the risk isn't just falling behind — it's becoming irrelevant. Huang has a different vision: sovereign AI. Not isolation, but autonomy — building national AI systems aligned with local values, independent of foreign tech giants. 'The data belongs to you,' Huang said. 'It belongs to your people, your country... your culture, your history, your common sense.' But fears over AI misuse remain potent — from surveillance and deepfake propaganda to job losses and algorithmic discrimination. Huang doesn't deny the risks. But he insists the technology can be kept in check — by itself. 'In the future, the AI that is doing the task is going to be surrounded by 70 or 80 other AIs that are supervising it, observing it, guarding it, ensuring that it doesn't go off the rails.' The VivaTech event was part of Huang's broader European tour. He had already appeared at London Tech Week and is scheduled to visit Germany. In Paris, he joined French President Emmanuel Macron and Mistral AI CEO Arthur Mensch to reinforce his message that AI is now a national priority. — Chan reported from London.
Yahoo
20 minutes ago
- Yahoo
Wall Street on Edge: Inflation Spike, $58B Debt Test, and Trade Turmoil Collide
Wall Street is holding its breath as two market-moving forces line up: inflation and debt. Investors are watching closely as the U.S. and China restart trade talks in London, aiming to ease tensions and avoid another round of tariff escalations. Meanwhile, a $58 billion Treasury auction could test demand for U.S. debt at a time when long-end yields hover near 5%a level many thought would spark broader market reactions. BMO's Ian Lyngen calls this week's combo of May CPI and Treasury supply a tradable event, with core inflation expected to accelerate to 2.9% year-over-yearthe first uptick of the year. The S&P 500 (SPY) sits roughly 2% from its February peak, but volatility could return fast depending on how these numbers land. Warning! GuruFocus has detected 5 Warning Sign with META. Despite the rebound from April's tariff-driven slide, institutional investors have yet to jump back into equities in full force. Deutsche Bank notes that institutional positioning has been this low less than a quarter of the time since 2010. JPMorgan and Barclays, however, suggest the tide could be turning, with more big money managers set to ramp up equity exposure. That shift hasn't shown up yetBank of America's clients were net sellers last week, with institutions pulling out while hedge funds and retail buyers stepped in. Strategist Jill Carey Hall thinks the market may have already priced in much of the deglobalization risk, but not the potential upside from underappreciated tax policy tailwinds. On the corporate front, action is heating up. Tesla (NASDAQ:TSLA) isn't grabbing headlines today, but its peers are moving fast. Meta's (NASDAQ:META) CEO Mark Zuckerberg is going all-in on artificial general intelligence, quietly assembling a powerhouse team to build out the next big wave in AI. Boeing (NYSE:BA) just secured its biggest monthly order tally in over a yearmuch of it inked during President Trump's trip to the Middle East. Cisco (NASDAQ:CSCO) is rolling out new AI-powered upgrades across its networking portfolio to stay competitive in the enterprise race. Taiwan Semiconductor (NYSE:TSM) posted a 40% revenue surge in May as chipmakers rushed to build inventory ahead of potential trade roadblocks. Not everything was rosyMcDonald's (NYSE:MCD) was slapped with a rare sell rating from Redburn Atlantic, and Citigroup (NYSE:C) is preparing to book hundreds of millions more in loan loss provisions, signaling early cracks in consumer credit health. This article first appeared on GuruFocus.
Yahoo
20 minutes ago
- Yahoo
QUALCOMM (QCOM) to Acquire Alphawave for $2.4 Billion in Data Center Expansion Push
QUALCOMM Incorporated (NASDAQ:QCOM) is one of the 10 AI Stocks on Wall Street's Radar. On June 9, the company reported that it has agreed to buy semiconductor company Alphawave IP Group Plc for an estimated $2.4 billion in cash, aiming to expand its technology and key assets for expanding into data centers. The companies revealed in a Monday statement that the offer is equivalent to about 183 pence per share for Alphawave, a 96% premium to the company's share price on March 31. This was the last trading day prior to the companies disclosing the deal discussion. While the deal is subject to regulatory and shareholder approval, it is anticipated to close in the first quarter of 2026. A medical staff analyzing data in an occupational health center. 'The acquisition of Alphawave Semi aims to further accelerate and provide key assets for Qualcomm's expansion into data centers,' the company said. While Qualcomm has made two alternative all-share offers for Alphawave following multiple deadline extensions from the UK takeover panel, Alphawave plans to unanimously recommend the cash offer to its shareholders. They deem it to be fair and reasonable. 'Under Tony's leadership Alphawave Semi has developed leading high-speed wired connectivity and compute technologies that are complementary to our power-efficient CPU and NPU cores. Qualcomm's advanced custom processors are a natural fit for data center workloads. The combined teams share the goal of building advanced technology solutions and enabling next-level connected computing performance across a wide array of high growth areas, including data center infrastructure.' – Cristiano Amon, president and CEO of Qualcomm Incorporated. QUALCOMM Incorporated (NASDAQ:QCOM) develops wireless technologies, supplies chips for mobile, automotive, and IoT devices, licenses patents, and invests in emerging industries worldwide. While we acknowledge the potential of QCOM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio
